<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438927</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Influence of SARS-CoV-2 variants on COVID-19 epidemiological and clinical profiles: a comparative analysis of two waves of cases.</ArticleTitle><Pagination><StartPage>260</StartPage><MedlinePgn>260</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">260</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02538-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic has been the most significant health challenge of the last century. Multiple and successive waves of COVID-19 cases, driven particularly by the emergence of new SARS-CoV-2 variants, have kept the world in a constant state of alert.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We present an observational, descriptive, cross-sectional study aimed at identifying SARS-CoV-2 variants circulating during two local waves of COVID-19 cases in southern Bahia, Brazil (late 2021 and late 2022), and analyzing the association between the detected variants and the epidemiological and clinical characteristics of the disease. For this purpose, data and nasopharyngeal samples from individuals in southern Bahia, Brazil, with suspected COVID-19 were included. Viral detection was performed by RT-qPCR, and SARS-CoV-2 variants were identified by next-generation viral sequencing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 368 nasopharyngeal samples were tested. Approximately 23% of the samples from late 2021 tested positive for SARS-CoV-2, while in 2022, the positivity rate was about 56%. All sequenced samples from 2021 were identified as the Delta variant, while in 2022, all samples were classified as the Omicron variant. Overall, individuals who tested positive for SARS-CoV-2 in 2022 were younger than those who tested positive in 2021. Moreover, we observed significant differences in the clinical spectrum of SARS-CoV-2 infection when comparing the two periods. Individuals who presented with anosmia/ageusia were more likely to test positive for SARS-CoV-2 infection in 2021 but not in 2022. Additionally, fever, dry cough, pharyngalgia, headache, and rhinorrhea were more frequent among individuals infected with the Omicron variant than among those infected with the Delta variant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The profile of COVID-19 in southern Bahia differed when analyzing two distinct waves of the pandemic in the region. These differences are likely related to the variants, which may differ in transmissibility and virulence, thereby altering the dynamics of the pandemic. This underscores the importance of genomic surveillance in better understanding the behavior of viral infections.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Pérola Rodrigues</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pós-Graduação em Ciências da Saúde, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Uener Ribeiro</ForeName><Initials>UR</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade AGES de Medicina de Irecê, Colegiado de Ciências Biológicas e da Saúde, Irecê, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Santana Silva</LastName><ForeName>Íris Terezinha Santos</ForeName><Initials>ÍTS</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Biologia e Biotecnologia de Microrganismos, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehlberg</LastName><ForeName>Hllytchaikra Ferraz</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Ciência Animal, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Fabrício Barbosa</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Biologia e Biotecnologia de Microrganismos, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albuquerque</LastName><ForeName>George Rego</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciências Agrárias e Ambientais, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariano</LastName><ForeName>Ana Paula Melo</ForeName><Initials>APM</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciências Biológicas, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Murillo Ferreira</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Biologia e Biotecnologia de Microrganismos, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemos</LastName><ForeName>Leonardo Santos</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pós-Graduação em Ciências da Saúde, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piton</LastName><ForeName>Karoline Almeida</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Melo Silva</LastName><ForeName>Mylene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciências Biológicas, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontana</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciências Biológicas, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guimarães Rocha Aguiar</LastName><ForeName>Eric Roberto</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Departamento de Engenharias e Computação, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Lauro Juliano</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadelha</LastName><ForeName>Sandra Rocha</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Laboratório de Farmacogenômica e Epidemiologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil. srgmello@uesc.br.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciências Biológicas, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brasil. srgmello@uesc.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Genomic surveillance</Keyword><Keyword MajorTopicYN="N">RT-qPCR</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438927</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02538-0</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02538-0</ArticleId><ArticleId IdType="pmc">PMC11515746</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–60. 10.23750/abm.v91i1.9397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization (PAHO). Histórico da Pandemia de COVID-19. 2023. Available online: https://www.paho.org/pt/covid19/historico-da-pandemia-covid-19. Accessed on July 12, 2024.</Citation></Reference><Reference><Citation>World Health Organization (WHO). COVID-19 vaccination, World data. 2024. Available online: https://data.who.int/dashboards/covid19/vaccines?n=c. Accessed on July 12, 2024.</Citation></Reference><Reference><Citation>Our World in Data. Coronavirus (COVID-19) Vaccinations. 2024. Available online: https://ourworldindata.org/covid-vaccinations/. Accessed on July 12, 2024.</Citation></Reference><Reference><Citation>Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, et al. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2022;12:1–21. 10.3389/fimmu.2021.809244.</Citation></Reference><Reference><Citation>Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa A, El-Ella D, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54:524–40. 10.1080/07853890.2022.2031274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8843115</ArticleId><ArticleId IdType="pubmed">35132910</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ER. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int J Biol Macromol. 2022;204:161–8. 10.1016/j.ijbiomac.2022.01.118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782737</ArticleId><ArticleId IdType="pubmed">35074332</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra R, Chakraborty S, et al. Global emerging Omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2023;16:04–14. 10.1016/j.jiph.2022.11.024.</Citation></Reference><Reference><Citation>Adeyemi OO, Ndodo ND, Sulaiman MK, Ayansola OT, Buhari OIN, Akanbi OA, et al. SARS-CoV-2 variants-associated outbreaks of COVID-19 in a tertiary institution, North-Central Nigeria: implications for epidemic control. PLoS ONE. 2023;18:1–18. 10.1371/journal.pone.0280756.</Citation></Reference><Reference><Citation>Gong W, Parkkila S, Wu X, Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies. Int Rev Immunol. 2023;42:393–414. 10.1080/08830185.2022.2079642.</Citation><ArticleIdList><ArticleId IdType="pubmed">35635216</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. Evolution patterns of SARS-CoV-2: snapshot on its genome variants. Biochem Biophys Res Commun. 2021;538:88–91. 10.1016/j.bbrc.2020.10.102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836704</ArticleId><ArticleId IdType="pubmed">33199021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning JS, Voo KE, Higham S, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626–36. 10.1038/s41577-021-00592-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhang H, Zhang W. SARS-CoV-2 variants, immune escape, and countermeasures. Front Med. 2022;16:196–207. 10.1007/s11684-021-0906-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8898658</ArticleId><ArticleId IdType="pubmed">35253097</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, et al. Insights for COVID-19 in 2023. Rev Esp Quimioter. 2023;36:114–24. 10.37201/req/122.2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10066911</ArticleId><ArticleId IdType="pubmed">36510683</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Statement on the update of WHO’s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest. 2023. Available online: https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest. Accessed on July 25, 2024.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;18:1708–20. 10.1056/NEJMoa2002032.</Citation></Reference><Reference><Citation>Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53:404–12. 10.1016/j.jmii.2020.02.012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128959</ArticleId><ArticleId IdType="pubmed">32173241</ArticleId></ArticleIdList></Reference><Reference><Citation>Endeshaw Y, Campbell K. Advanced age, comorbidity and the risk of mortality in COVID-19 infection. J Natl Med Assoc. 2022;114:512–7. 10.1016/j.jnma.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189096</ArticleId><ArticleId IdType="pubmed">35786506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Marzook H, Ahmad F. Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. Clin Exp Med. 2023;23:313–31. 10.1007/s10238-022-00821-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8972750</ArticleId><ArticleId IdType="pubmed">35362771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS ONE. 2021;16(7):e0254066. 10.1371/journal.pone.0254066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270145</ArticleId><ArticleId IdType="pubmed">34242273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, Blomquist P, Zaidi A, Volz E, Aziz NA, Harman K, Funk S, Abbott S, COVID-19 Genomics UK (COG-UK) consortium, Hope R, Charlett A, Chand M, Ghani AC, Seaman SR, Dabrera G, De Angelis D, Presanis AM, Thelwall S. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399:1303–12. 10.1016/S0140-6736(22)00462-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022. Eurosurveillance. 2022;27:2200077. 10.2807/1560-7917.ES.2022.27.4.2200077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796289</ArticleId><ArticleId IdType="pubmed">35086614</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38–42. 10.1016/j.ijid.2021.12.357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8713416</ArticleId><ArticleId IdType="pubmed">34971823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, Ye C, Zhang P, Xing Y, Guo H, Tang W. Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:16–25. 10.1016/j.jinf.2020.04.021.</Citation></Reference><Reference><Citation>Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. PLoS Pathog. 2020;16(6):e1008570. 10.1371/journal.ppat.1008570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307725</ArticleId><ArticleId IdType="pubmed">32569293</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva MF, dos Santos UR, Ferreira FB, Albuquerque GR, Mariano APM, Fehlberg HF, Santos de Santana ÍT, dos Santos PR, Santos LC, Silva de Jesus LL, et al. SARS-CoV-2 infection in cities from the Southern Region of Bahia State, Brazil: analysis of variables Associated in both Individual and Community Level. Viruses. 2023;15:1583. 10.3390/v15071583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10383252</ArticleId><ArticleId IdType="pubmed">37515269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasylyeva TI, Havens JL, Wang JC, Luoma E, Hassler GW, et al. The role of socio-economic disparities in the relative success and persistence of SARS-CoV-2 variants in New York City in early 2021. PLoS Pathog. 2024;20:e1012288. 10.1371/journal.ppat.1012288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11218943</ArticleId><ArticleId IdType="pubmed">38900824</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha R, Atun R, Massuda A, Rache B, Spinola P, Nunes L, Lago M, Castro MC. Effect of socioeconomic inequalities and vulnerabilities on health-system preparedness and response to COVID-19 in Brazil: a comprehensive analysis. Lancet Glob Health. 2021;9:782–92. 10.1016/S2214-109X(21)00081-4.</Citation></Reference><Reference><Citation>Rangel MC. A crise do território-região cacaueira da Bahia: Os nós discursivos nas tramas do poder local para manter o território – 1980–2010. [PhD thesis]. Maringá: Universidade Estadual de Maringá; 2013.</Citation></Reference><Reference><Citation>O’Toole Á, Scher E, Underwood A et al. Pangolin COVID-19 Lineage Assigner, COVID-19 Lineage. 2020. Available online: https://cov-lineages.org/resources/pangolin.html. Accessed on March 12, 2024.</Citation></Reference><Reference><Citation>Dutta A. COVID-19 waves: variant dynamics and control. Sci Rep. 2022;12:9332. 10.1038/s41598-022-13371-2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166180</ArticleId><ArticleId IdType="pubmed">35661125</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura EC, Cortez-Escalante J, Cristina I, Barreto DHC, Sanchez MN, Maria L, et al. Covid-19: evolução temporal e imunização nas três ondas. Rev Saude Publica. 2022;56:1–11. 10.11606/s1518-8787.2022056004907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849287</ArticleId><ArticleId IdType="pubmed">35239924</ArticleId></ArticleIdList></Reference><Reference><Citation>Nivette A, Ribeaud D, Murray A, Steinhoff A, Bechtiger L, Hepp U, et al. Non-compliance with COVID-19-related public health measures among young adults in Switzerland: insights from a longitudinal cohort study. Soc Sci Med. 2021;268. 10.1016/j.socscimed.2020.113370.</Citation></Reference><Reference><Citation>Ravert RD, Ph D, Fu LY, Zimet SM, Ph GD. Young adults’ COVID-19 testing intentions: the role of Health beliefs and Anticipated Regret. J Adolesc Heal. 2021;68:460–3. 10.1016/j.jadohealth.2020.12.001.</Citation></Reference><Reference><Citation>Instituto Brasileiro de Geografia e Estatística (IBGE). Censo Demográfico. Tabela 9514 - População residente, por sexo, idade e forma de declaração da idade. Available online: https://sidra.ibge.gov.br/tabela/9514. Accessed on June 12, 2024.</Citation></Reference><Reference><Citation>Silva JP, de Lima AB, Alvim LB, Malta FSV, Mendonça CPTB, Fonseca PLC, et al. Delta variant of SARS-CoV-2 replacement in Brazil: a national epidemiologic Surveillance Program. Viruses. 2022;14. 10.3390/v14050847.</Citation></Reference><Reference><Citation>Secretaria da Saúde do Estado da Bahia (SESAB). Laboratório Central de Saúde Pública – LACEN/BA. Boletim informativo: Sequenciamento SARS-CoV-2. Edição nº 13/2022. 2022. Available online: https://www.saude.ba.gov.br/wp-content/uploads/2022/03/15.03-BOLETIM-INFORMATIVO-SEQUENCIAMENTO-LACEN-EDICAO-13-1.pdf. Accessed on April 15, 2024.</Citation></Reference><Reference><Citation>Wolf JM, Wolf LM, Bello GL, Maccari JG, Nasi LA. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. J Med Virol. 2023;95:1–10. 10.1002/jmv.28366.</Citation></Reference><Reference><Citation>Secretaria da Saúde do Estado da Bahia (SESAB). Laboratório Central de Saúde Pública – LACEN/BA. Boletim informativo: Sequenciamento SARS-CoV-2. Edição nº 7/2022. 2022. Available online: https://www.saude.ba.gov.br/wp-content/uploads/2022/12/30.12.22-BOLETIM-INFORMATIVO-SEQUENCIAMENTO-LACEN-EDICAO-07.2022.pdf. Accessed on April 15, 2024.</Citation></Reference><Reference><Citation>Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603:687–92. 10.1038/s41586-022-04441-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021. 10.1038/d41586-021-03829-0.</Citation><ArticleIdList><ArticleId IdType="pubmed">34937889</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H, Chan JFW, Hu B, Chai Y, Yuen TTT, Yin F, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603:693–9. 10.1038/s41586-022-04442-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35062016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia L, Xu M, Hao M, Liu D, Liu H, Zheng X, et al. Comparison of microbial composition and diversity in the upper respiratory tract between SARS-CoV-2 and influenza virus infections. Sci China Life Sci. 2022;65:1469–72. 10.1007/s11427-021-2092-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8962226</ArticleId><ArticleId IdType="pubmed">35349047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>